0.6417
1.28%
-0.0083
Viracta Therapeutics Inc stock is currently priced at $0.6417, with a 24-hour trading volume of 57,886.
It has seen a -1.28% decreased in the last 24 hours and a -16.77% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.6533 pivot point. If it approaches the $0.6167 support level, significant changes may occur.
Previous Close:
$0.65
Open:
$0.65
24h Volume:
57,886
Market Cap:
$25.20M
Revenue:
-
Net Income/Loss:
$-51.06M
P/E Ratio:
-0.465
EPS:
-1.38
Net Cash Flow:
$-40.03M
1W Performance:
+1.07%
1M Performance:
-16.77%
6M Performance:
+33.69%
1Y Performance:
-58.60%
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Name
Viracta Therapeutics Inc
Sector
Industry
Phone
858 400 8470
Address
2533 South Coast Highway 101, Suite 210, Cardiff-by-the-Sea
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-01-22 | Initiated | RBC Capital Mkts | Outperform |
May-03-21 | Initiated | H.C. Wainwright | Buy |
Apr-26-21 | Initiated | SVB Leerink | Outperform |
Mar-25-21 | Initiated | Evercore ISI | Outperform |
Viracta Therapeutics Inc Stock (VIRX) Latest News
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year? - Yahoo Singapore News
Yahoo Singapore News
Stock Surge: Viracta Therapeutics Inc (VIRX) Closes at 0.67, Marking a -9.27 Increase/Decrease – DWinneX - The Dwinnex
The Dwinnex
Viracta Therapeutics (NASDAQ:VIRX) Price Target Lowered to $11.00 at Oppenheimer - Defense World
Defense World
Viracta Therapeutics stock target cut by Oppenheimer By Investing.com - Investing.com Canada
Investing.com Canada
RBC Capital Reiterates Viracta Therapeutics (VIRX) Outperform Recommendation - MSN
MSN
Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
GlobeNewswire
Viracta Therapeutics Inc Stock (VIRX) Financials Data
Viracta Therapeutics Inc (VIRX) Net Income 2024
VIRX net income (TTM) was -$51.06 million for the quarter ending December 31, 2023, a -3.78% decrease year-over-year.
Viracta Therapeutics Inc (VIRX) Cash Flow 2024
VIRX recorded a free cash flow (TTM) of -$40.03 million for the quarter ending December 31, 2023, a -12.75% decrease year-over-year.
Viracta Therapeutics Inc (VIRX) Earnings per Share 2024
VIRX earnings per share (TTM) was -$1.32 for the quarter ending December 31, 2023, a -1.54% decline year-over-year.
About Viracta Therapeutics Inc
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Cap:
|
Volume (24h):